Antimetastasis therapy: Metformin, the widley used drug in the treatment of T2M, suppresses the expression of actin-regulatory proteins FHOD1 and PPM1F and inhibits migration and invasion of metastatic cancer cells via up regulation of its target gene, 25/March/2015, 21.55

MiRNA-based antimetastasis therapy: MiRNA-222 inhibits epithelial-mesenchymal transition and cancer cell proliferation via down regulation of GLUT3, 25/March/2015, 14.56
March 25, 2015
Expose yourself to optimal Sunlight to live longer: Nitric oxide (endogenous) inhibits senescence and extends life span by down regulating the expression of adenylate cyclase 5 (ADCY5), 25/March/2014, 22.10
March 25, 2015
Show all

Idea Proposed/Formulated byDr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

CitationBoominathan, L., Antimetastasis therapy: Metformin, the widley used drug in the treatment of T2M, suppresses the expression of actin-regulatory proteins FHOD1 and PPM1F and inhibits migration and invasion of metastatic cancer cells via up regulation of its target gene, 25/March/2015, 21.55, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Significance: The study presented here suggests that Metformin, by increasing the expression of its target genes, it may suppress the expression of actin-regulatory proteins FHOD1 and PPM1F. Thereby, it may inhibit migration and invasion of metastatic cancer cells. Thus, pharmacological formulations encompassing “Metformin or its analogues” may be used to inhibit the progression of invasive tumors.

Undisclosed information: How Metformin  decreases the expression of FHOD1 and PPM1F

Web: http://genomediscovery.org

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.